IGF1R and cancer: Short-chain oligosaccharides (HS06) can enter a unique pocket in the IGF-1R ectodomain and compete with the natural cognate ligand IGF-1, thereby blocking the physiological processes mediated by IGF-1R and exerting anti-cancer effects [108].